Methods of treating multiple sclerosis
AssigneeVanda Pharmaceuticals Inc.
InventorsAllitia DiBernardo, Maria Ait-Tihyaty
Life of this patent
Estimating the term…
Abstract
The disclosure relates to methods of treating multiple sclerosis. In certain aspects, methods of treating early-stage multiple sclerosis in a patient are disclosed.
Claims30
A method of treating a patient suffering from early-stage multiple sclerosis (ESMS), the method comprising:
- determining an expanded disability status scale (EDSS) score of the patient;
- identifying the patient as having early-stage multiple sclerosis (ESMS) in the case that the patient has an EDSS score that is ≤3.0;
- and
- administering ponesimod to the patient using a regimen that is effective to treat the ESMS.
A method of treating a patient suffering from early-stage multiple sclerosis (ESMS), the method comprising:
- determining an expanded disability status scale (EDSS) score of the patient;
- identifying the patient as having ESMS in the case that the patient has an EDSS score that is ≤3.0;
- and
- administering ponesimod to the patient using a regimen that is effective to reduce the number of combined unique active lesions (CUALs) in the patient by at least 50%, relative to a patient population at substantially the same level of disease progression receiving a standard of care treatment that does not comprise ponesimod.
A method of treating a patient suffering from early-stage multiple sclerosis (ESMS), the method comprising:
- determining an expanded disability status scale (EDSS) score of the patient;
- identifying the patient as having ESMS in the case that the patient has an EDSS score that is ≤3.0;
- and
- administering ponesimod to the patient using a regimen that is effective to reduce the annualized relapse rate (ARR) in the patient by at least 25%, relative to a patient population at substantially the same level of disease progression receiving a standard of care treatment that does not comprise ponesimod.
A method of treating a patient suffering from early-stage multiple sclerosis (ESMS) and fatigue, the method comprising:
- determining an expanded disability status scale (EDSS) score of the patient;
- identifying the patient as having ESMS in the case that the patient has an EDSS score that is ≤3.0;
- and
- administering ponesimod to the patient using a regimen that is effective to reduce MS-fatigue mean difference to about −4%, relative to a patient population at substantially the same level of disease progression receiving a standard of care treatment that does not comprise ponesimod.
Dependencies are inferred from the claim text.